OHE Publications

OHE releases a number of publications throughout the year, authored by OHE team members and/or outside experts. All are free for download as pdf files; hard copies of some publications are available upon request.

A description of the OHE publications categories.


 

Marsden, G., Martin, A., Zamora, B., Exley, J., Sussex, J. and Towse, A.

Consulting Report
September 2016

The Oxford Academic Health Science Network (Oxford AHSN) wishes to demonstrate the value of the various projects and programmes that the network has developed and implemented since it was established in 2013.

Cole, A., Marsden, G., Devlin, N., Grainger, D., Lee, E.K. and Oortwijn, W.

Briefing
August 2016

This report provides a detailed summary of a panel session which took place at the HTAi 2016 annual meeting in Tokyo. The panel session was entitled "New Age Decision Making in HTA: Is It Applicable in Asia?". To open the session, David Grainger (Eli Lilly & Company) provided an overview of the session, offering useful background information on the topic. 

Cole, A., Chan, A., Mujoomdar, M., Pichler, F. and Towse, A.

Briefing
August 2016

This report provides a detailed summary of a panel session which took place at the HTAi 2016 annual meeting, Tokyo. The panel session was entitled "How Can HTA in Asia-Pacific Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?" and was chaired by Franz Pichler (Eli Lilly & Company).

Karlsberg Schaffer, S., Cubi-Molla, P., Devlin, N. and Towse, A.

Consulting Report
April 2016

This report details the views of a selection of experts in the fields of health and welfare economics on the cost-effectiveness threshold used by the National Institute for Health and Care Excellence (NICE) to decide which new medicines to recommend for use in the NHS, and the direction of future research in this  area.

O'Neill, P. and Zamora, B.

Consulting Report
February 2016
The objective of this OHE Consulting Report was to outline trends in Scottish Medicines Committee (SMC) advice decisions for medicines for the period October 2009 to September 2015. This report was initiated and funded by Pfizer Ltd. It specifically considers whether there were changes in the trends due to the adoption of new policies by the SMC, namely the increased use of modifiers when assessing cost-effectiveness (e.g.

Sussex, J. and Hernandez-Villafuerte, K.

Research Paper
December 2015

This paper presents a model to capture the behaviour of health sector decision makers when making resource allocation decisions on the level and mix of healthcare production, while taking into consideration the maximum expenditure (budget) allowed by the government or the health system regulator.

The paper seeks to address two perennial policy and practical discussions in the UK National Health Service (NHS) (and elsewhere): how to cope with financial austerity; and the opportunity costs of reimbursing new health technologies.

Cole, A., Garrison, L., Mestre-Ferrandiz, J. and Towse, A.

Consulting Report
November 2015

The objective of this OHE Consulting Report was to understand and develop a view on the core principles that should govern how Real-World Data (RWD) is accessed or generated, and used credibly to produce or generate Real-World Evidence (RWE), thereby working toward a set of “international standards”.

O'Neill, P. and Sussex, J.

Consulting Report
May 2015

The OHE undertook an analysis of the uptake of medicines in 13 high income countries. The UK perspective on this was published in November 2014 by the ABPI. OHE has been commissioned by LIF, the trade association of the pharmaceutical industry in Sweden, to reanalyse the international comparison of medicines uptake from the Swedish perspective; and the results are available here and on LIF’s website.

Pages